Literature DB >> 24947638

Early pregnancy exposure to antihistamines and risk of congenital heart defects: results of two case-control studies.

Huberdina P M Smedts1, Linda de Jonge, Sarah J G Bandola, Marlies E Baardman, Marian K Bakker, Bruno H C Stricker, Régine P M Steegers-Theunissen.   

Abstract

UNLABELLED: We aimed to study the association between use of antihistamines in early pregnancy and congenital heart defects (CHD) in the offspring.
DESIGN: Two case-control studies.
SETTING: HAVEN study, Erasmus MC, University Medical Centre, Rotterdam, and Eurocat Northern Netherlands (NNL), University Medical Center Groningen, Groningen, the Netherlands. We studied 361 children with CHD and 410 controls without congenital malformations from the HAVEN study and replicated the analyses in 445 children with CHD and 530 controls from the Eurocat NNL registry. Information about antihistamine use in early pregnancy and potential confounders was obtained from questionnaires postpartum. We calculated the association between antihistamines and CHD risk by multivariable logistic regression analysis. MAIN OUTCOME MEASURES: Odds ratios (OR) with 95% confidence intervals (CI). In the HAVEN study, 25 of 771 mothers used antihistamines that were associated with an increased CHD risk (OR 3.0, 95% CI 1.2-7.3), particularly atrioventricular septal defects (AVSD) (OR 5.1, 95 % CI 1.3-20.5) and perimembranous ventricular septal defects (pVSD) (OR 5.1, 95% CI 1.8-14.4). Mothers with severe nausea who did not use antihistamines had a reduced risk (OR 0.7, 95% CI 0.5-0.98), whereas nauseous mothers using antihistamines showed an almost fivefold increased risk of pVSD (OR 4.8, 95% CI 1.1-21.8). The association between antihistamines and AVSD was confirmed in the Eurocat cohort (OR 3.5, 95% CI 1.4-8.7), but we could not replicate the association with overall CHD risk. We found a positive association between antihistamine use in early pregnancy and CHD risk, particularly AVSD, which seemed to be independent of nausea/vomiting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24947638     DOI: 10.1007/s10654-014-9925-0

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  28 in total

1.  ANTIHISTAMINES AND TERATOGENICITY IN THE RAT.

Authors:  C T KING; S A WEAVER; S A NARROD
Journal:  J Pharmacol Exp Ther       Date:  1965-03       Impact factor: 4.030

2.  Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis.

Authors:  A Seto; T Einarson; G Koren
Journal:  Am J Perinatol       Date:  1997-03       Impact factor: 1.862

3.  Inverse association between severe nausea and vomiting in pregnancy and some congenital abnormalities.

Authors:  Andrew E Czeizel; Erzsébet Puhó; Nándor Acs; Ferenc Bánhidy
Journal:  Am J Med Genet A       Date:  2006-03-01       Impact factor: 2.802

4.  The safety of cetirizine during pregnancy. A prospective observational cohort study.

Authors:  Corinna Weber-Schoendorfer; Christof Schaefer
Journal:  Reprod Toxicol       Date:  2008-05-13       Impact factor: 3.143

5.  Thalidomide: was the tragedy preventable?

Authors:  A Dally
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

Review 6.  Nausea and vomiting in early pregnancy: its role in placental development.

Authors:  R R Huxley
Journal:  Obstet Gynecol       Date:  2000-05       Impact factor: 7.661

7.  Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study.

Authors:  P W Yoon; R S Olney; M J Khoury; W M Sappenfield; G F Chavez; D Taylor
Journal:  Arch Pediatr Adolesc Med       Date:  1997-11

8.  Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.

Authors:  P M McKeigue; S H Lamm; S Linn; J S Kutcher
Journal:  Teratology       Date:  1994-07

Review 9.  Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis.

Authors:  Thomas R Einarson; Charles Piwko; Gideon Koren
Journal:  J Popul Ther Clin Pharmacol       Date:  2013-07-13

Review 10.  Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.

Authors:  Mary Ella Pierpont; Craig T Basson; D Woodrow Benson; Bruce D Gelb; Therese M Giglia; Elizabeth Goldmuntz; Glenn McGee; Craig A Sable; Deepak Srivastava; Catherine L Webb
Journal:  Circulation       Date:  2007-05-22       Impact factor: 29.690

View more
  2 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011.

Authors:  Craig Hansen; Tania A Desrosiers; Kathy Wisniewski; Matthew J Strickland; Martha M Werler; Suzanne M Gilboa
Journal:  Birth Defects Res       Date:  2020-07-13       Impact factor: 2.661

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.